Atossa Therapeutics' Bold Moves in Breast Cancer Treatment
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is making waves in the oncology sector, focusing on innovative therapies for breast cancer. The company has recently announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the renowned San Antonio Breast Cancer Symposium (SABCS), scheduled for December 2025.
Significance of (Z)-Endoxifen in Cancer Treatment
(Z)-Endoxifen is gaining recognition for its potential in transforming breast cancer treatment paradigms. Research indicates that this compound could play a vital role in not just treatment, but also in the prevention of breast cancer. As Dr. Steven Quay, President and CEO of Atossa, points out, the company is dedicated to increasing the body of clinical evidence surrounding this promising compound.
Presentation Highlights and Topics
Details of the Presentations
Attendees at SABCS 2025 can look forward to compelling poster presentations that outline the findings from studies assessing (Z)-endoxifen's efficacy. The presentations will showcase research that includes:
- Initial results from RECAST DCIS: This multicenter platform trial evaluates active surveillance along with novel endocrine therapy agents for managing Ductal Carcinoma In Situ (DCIS).
- Low dose (Z)-endoxifen: Findings from the I-SPY2 Endocrine Optimization Pilot will also be revealed.
- ER? Antagonist Function: Exploring how (Z)-endoxifen maintains activity against specific mutants through various mechanisms.
- Neoadjuvant Treatment Approaches: A randomized Phase 2 trial comparing (Z)-endoxifen in combination with Goserelin versus traditional therapies for premenopausal women with ER+/HER2- breast cancer.
Anticipation for SABCS 2025
The anticipation for SABCS 2025 is palpable within the oncology community. With a commitment to rigorous clinical evidence, Atossa Therapeutics is set to shine a spotlight on important findings that could influence future treatment strategies. By presenting these innovative studies, the company hopes to engage with healthcare professionals and stakeholders dedicated to advancing breast cancer care.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a forward-thinking clinical-stage biopharmaceutical firm focused on addressing significant unmet needs in the breast cancer landscape. Through strategic resource allocation and an emphasis on impactful data, Atossa aims to facilitate future regulatory submissions and ultimately bring its therapies to market.
Frequently Asked Questions
What is (Z)-endoxifen?
(Z)-Endoxifen is a metabolic derivative of tamoxifen that shows promise in breast cancer treatment and prevention.
Where will the SABCS 2025 take place?
The San Antonio Breast Cancer Symposium is scheduled to happen in San Antonio, Texas.
Who is presenting the abstracts at SABCS?
Dr. Steven Quay, the President and CEO of Atossa Therapeutics, will represent the company during the presentations at SABCS.
What are the key topics of discussion regarding (Z)-endoxifen?
Key topics include its role in treating DCIS, its effectiveness as a low-dose therapy, and its function against ESR1 mutants.
How can I find more information about Atossa Therapeutics?
More details about Atossa Therapeutics can be found on their official website and in their filings with the U.S. Securities and Exchange Commission.